Silexion completes toxicology studies for SIL204; Phase 2/3 trial on track for Q2 2026

Silexion Therapeutics Corp

Two-species toxicology studies for SIL204 confirm no systemic organ toxicity, clearing path to regulatory filings.
Regulatory submissions planned to Israel Ministry of Health and Germany's BfArM ahead of Phase 2/3 trial.
Phase 2/3 clinical trial in locally advanced pancreatic cancer (LAPC) expected to initiate in Q2 2026.
CRO partner for the trial has been secured; SIL204 targets mutant KRAS oncogenes via siRNA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.